MIST [NASD]
Milestone Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.05 Insider Own9.28% Shs Outstand42.24M Perf Week-9.09%
Market Cap153.52M Forward P/E- EPS next Y-1.63 Insider Trans0.00% Shs Float27.15M Perf Month-26.13%
Income-44.30M PEG- EPS next Q-0.37 Inst Own75.20% Short Float6.89% Perf Quarter-13.46%
Sales15.00M P/S10.23 EPS this Y39.80% Inst Trans0.05% Short Ratio17.25 Perf Half Y-3.57%
Book/sh2.39 P/B2.26 EPS next Y-54.70% ROA-35.10% Target Price14.40 Perf Year-2.70%
Cash/sh3.52 P/C1.53 EPS next 5Y- ROE-36.90% 52W Range3.98 - 8.24 Perf YTD-17.56%
Dividend- P/FCF- EPS past 5Y- ROI-38.30% 52W High-34.34% Beta-
Dividend %- Quick Ratio22.80 Sales past 5Y- Gross Margin- 52W Low35.93% ATR0.52
Employees29 Current Ratio22.80 Sales Q/Q- Oper. Margin- RSI (14)35.21 Volatility8.70% 8.19%
OptionableYes Debt/Eq0.00 EPS Q/Q-9.30% Profit Margin- Rel Volume0.08 Prev Close5.40
ShortableYes LT Debt/Eq0.00 EarningsMay 12 BMO Payout- Avg Volume108.44K Price5.41
Recom1.80 SMA20-15.27% SMA50-12.32% SMA200-11.28% Volume1,070 Change0.19%
Apr-22-22Upgrade Piper Sandler Neutral → Overweight $8 → $10
Mar-05-21Initiated H.C. Wainwright Buy $20
Jul-29-20Upgrade Oppenheimer Perform → Outperform $18
Jul-24-20Upgrade Jefferies Hold → Buy
Mar-25-20Downgrade Jefferies Buy → Hold $28 → $3
Mar-24-20Downgrade Piper Sandler Overweight → Neutral $26.50 → $3
Mar-24-20Downgrade Oppenheimer Outperform → Perform
Jun-04-19Initiated Oppenheimer Outperform $32
Jun-03-19Initiated Piper Jaffray Overweight $26.50
Jun-03-19Initiated Jefferies Buy $28
Jun-03-19Initiated Cowen Outperform $32
May-12-22 07:15AM  
Apr-30-22 09:00AM  
09:00AM  
Apr-15-22 04:41PM  
04:41PM  
10:20AM  
Apr-14-22 07:00AM  
07:00AM  
Mar-24-22 07:20AM  
Mar-01-22 07:00AM  
07:00AM  
Feb-16-22 07:00AM  
07:00AM  
Feb-14-22 01:03PM  
Jan-04-22 07:00AM  
07:00AM  
Dec-14-21 07:56AM  
Nov-15-21 07:00AM  
Nov-12-21 07:20AM  
07:20AM  
Nov-11-21 07:00AM  
07:00AM  
Oct-15-21 09:31AM  
Sep-22-21 07:00AM  
07:00AM  
Sep-07-21 07:00AM  
07:00AM  
Aug-16-21 10:58AM  
Aug-11-21 04:18PM  
04:18PM  
Aug-03-21 09:01AM  
May-26-21 07:00AM  
07:00AM  
May-17-21 01:22PM  
07:02AM  
07:02AM  
07:01AM  
07:01AM  
07:00AM  
07:00AM  
May-04-21 09:04AM  
May-03-21 06:47AM  
Apr-02-21 11:59AM  
Mar-29-21 05:32PM  
05:32PM  
05:30PM  
05:30PM  
Mar-05-21 10:29AM  
Feb-25-21 07:00AM  
Feb-01-21 04:35AM  
Jan-29-21 05:13PM  
Dec-02-20 10:11PM  
06:08AM  
Nov-23-20 04:44PM  
07:00AM  
07:00AM  
Nov-18-20 07:00AM  
07:00AM  
Nov-13-20 07:00AM  
07:00AM  
Nov-11-20 07:00AM  
Oct-23-20 07:00AM  
07:00AM  
Oct-22-20 04:01PM  
04:01PM  
Sep-22-20 07:00AM  
Sep-08-20 07:00AM  
07:00AM  
Aug-12-20 07:00AM  
Aug-10-20 07:47AM  
Aug-06-20 07:00AM  
Aug-04-20 09:04AM  
Jul-31-20 12:34PM  
Jul-24-20 06:17PM  
02:19PM  
Jul-23-20 07:00AM  
07:00AM  
07:00AM  
Jun-12-20 06:39AM  
Jun-10-20 08:37AM  
Jun-05-20 02:46PM  
May-27-20 07:00AM  
May-20-20 10:00AM  
08:33AM  
May-19-20 07:22AM  
May-14-20 07:15AM  
07:15AM  
Apr-20-20 10:38AM  
Apr-02-20 01:23PM  
Apr-01-20 10:15AM  
Mar-25-20 10:34AM  
Mar-24-20 08:20AM  
Mar-23-20 11:08PM  
04:05PM  
Mar-06-20 07:00AM  
07:00AM  
Feb-04-20 09:22AM  
Jan-15-20 07:00AM  
Dec-20-19 06:20PM  
Nov-27-19 07:00AM  
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as in the Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate, and other cardiovascular indications. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil in patients with paroxysmal supraventricular tachycardia and additional cardiovascular conditions in Greater China. The company was incorporated in 2003 and is headquartered in Montreal, Canada.